RIGL

SEC source: 0000905148-26-004080 · form4.xml · derivative · entry 9

Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,867

Underlying: Common Stock · 1,286 shares

Expires 2030-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The shares of common stock subject to the option vested monthly over four (4) years from the vesting commencement date of January 1, 2020, subject to the Reporting Person's continuous service to the Issuer through each such period.

SEC source: 0000905148-26-004080 · form4.xml · derivative · entry 8

Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,999

Underlying: Common Stock · 2,000 shares

Expires 2032-01-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

F2 · shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

F5 · derivative.exercise_date: The shares of common stock subject to the option vested monthly over four (4) years from the vesting commencement date of January 1, 2022, subject to the Reporting Person's continuous service to the Issuer through each such period.

F2 · derivative.underlying_shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

F2 · balance_after: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

SEC source: 0000905148-26-004080 · form4.xml · derivative · entry 7

Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,012

Underlying: Common Stock · 620 shares

Expires 2033-01-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The shares of common stock subject to the option vest monthly over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer through each such period.

SEC source: 0000905148-26-004080 · form4.xml · derivative · entry 6

Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,824

Underlying: Common Stock · 694 shares

Expires 2034-01-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 23, 2024, subject to the Reporting Person's continuous service to the Issuer through each such period.

SEC source: 0000905148-26-004080 · form4.xml · nonDerivative · entry 5

Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,962

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000905148-26-004080 · form4.xml · nonDerivative · entry 4

Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,676

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

F2 · price: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

SEC source: 0000905148-26-004080 · form4.xml · nonDerivative · entry 3

Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,676

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000905148-26-004080 · form4.xml · nonDerivative · entry 2

Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,056

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000905148-26-004080 · form4.xml · nonDerivative · entry 1

Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,362

F1 · balance_after: Includes 500 shares acquired under the Issuer's stock purchase plan.

SEC source: 0000905148-26-004079 · form4.xml · nonDerivative · entry 1

Santos David A · CIK 0001820066 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,622

F1 · balance_after: Includes 500 shares acquired under the Issuer's stock purchase plan.

SEC source: 0000905148-26-004078 · form4.xml · nonDerivative · entry 1

RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 273,362

F1 · balance_after: Reflects the return to the Issuer of 3,807 shares previously reported as acquired under the Issuer's employee stock purchase plan.

SEC source: 0000905148-26-004077 · form4.xml · nonDerivative · entry 1

Furey Raymond J. · CIK 0001577899 · EVP, GC, CCO & Corp Sec

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,559

F1 · balance_after: Includes 500 shares acquired under the Issuer's stock purchase plan.

SEC source: 0000905148-26-003238 · form4.xml · nonDerivative · entry 1

HANNAH ALISON L. · CIK 0001645600 · EVP, Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,025

F1 · shares: The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over four (4) years from July 8, 2026, with the first annual vest occurring on July 8, 2027.

F2 · balance_after: Amount has been adjusted to reflect the cancellation of 5,750 restricted stock units for no consideration, which is exempt from Section 16 pursuant to Rule 16b-6(d) and Rule 16a-4(d) promulgated under the Securities Exchange Act of 1934, as amended.

SEC source: 0000905148-26-003076 · form4.xml · nonDerivative · entry 1

Ali-Jackson Kamil · CIK 0001654337 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,125

F1 · kind: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025.

F2 · kind: The shares sold in this transaction were sold to cover applicable tax withholding obligations incurred upon the vesting of restricted stock units and were not sold for investment purposes.

SEC source: 0000905148-26-003039 · form4.xml · derivative · entry 1

Furey Raymond J. · CIK 0001577899 · EVP, GC, CCO & Corp Sec

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,394

Underlying: Common Stock · 7,394 shares

Expires 2035-01-29

F1 · derivative.exercise_price: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

F1 · shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

F2 · derivative.exercise_date: The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.

F1 · derivative.underlying_shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

SEC source: 0000905148-26-003038 · form4.xml · derivative · entry 1

RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,700

Underlying: Common Stock · 31,700 shares

Expires 2035-01-29

F1 · derivative.exercise_price: The Reporting Person was granted a stock option with a performance-based condition with respect to 31,700 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

F1 · shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 31,700 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

F2 · derivative.exercise_date: The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.

F1 · derivative.underlying_shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 31,700 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

SEC source: 0000905148-26-003040 · form4.xml · derivative · entry 2

Rojkjaer Lisa · CIK 0001846460 · EVP, Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,394

Underlying: Common Stock · 7,394 shares

Expires 2035-01-29

F3 · derivative.exercise_price: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

F3 · shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

F4 · derivative.exercise_date: The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.

F3 · derivative.underlying_shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

SEC source: 0000905148-26-003040 · form4.xml · derivative · entry 1

Rojkjaer Lisa · CIK 0001846460 · EVP, Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,375

Underlying: Common Stock · 9,375 shares

Expires 2034-03-27

F1 · derivative.exercise_price: The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

F1 · shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

F2 · derivative.exercise_date: The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.

F1 · derivative.underlying_shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

SEC source: 0000905148-26-003037 · form4.xml · derivative · entry 1

Santos David A · CIK 0001820066 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,394

Underlying: Common Stock · 7,394 shares

Expires 2035-01-29

F1 · derivative.exercise_price: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

F1 · shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

F2 · derivative.exercise_date: The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.

F1 · derivative.underlying_shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

SEC source: 0000905148-26-003036 · form4.xml · derivative · entry 1

Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,394

Underlying: Common Stock · 7,394 shares

Expires 2035-01-29

F1 · derivative.exercise_price: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

F1 · shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

F2 · derivative.exercise_date: The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.

F1 · derivative.underlying_shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

SEC source: 0000905148-26-002811 · form4.xml · derivative · entry 5

Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,518

Underlying: Common Stock · 2,181 shares

Expires 2034-01-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

F1 · shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

F3 · derivative.exercise_date: The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 23, 2024, subject to the Reporting Person's continuous service to the issuer through each such period.

F1 · derivative.underlying_shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

F1 · balance_after: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

SEC source: 0000905148-26-002811 · form4.xml · derivative · entry 4

Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,632

Underlying: Common Stock · 1,200 shares

Expires 2033-01-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer through each such period.

SEC source: 0000905148-26-002811 · form4.xml · nonDerivative · entry 3

Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,790

SEC source: 0000905148-26-002811 · form4.xml · nonDerivative · entry 2

Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,718

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

F1 · price: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

SEC source: 0000905148-26-002811 · form4.xml · nonDerivative · entry 1

Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,537

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000905148-26-002810 · form4.xml · nonDerivative · entry 1

Santos David A · CIK 0001820066 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,996

SEC source: 0000905148-26-002809 · form4.xml · nonDerivative · entry 1

Rojkjaer Lisa · CIK 0001846460 · EVP, Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,003

SEC source: 0000905148-26-002808 · form4.xml · nonDerivative · entry 1

RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 279,593

SEC source: 0000905148-26-002807 · form4.xml · nonDerivative · entry 1

Furey Raymond J. · CIK 0001577899 · EVP, GC, CCO & Corp Sec

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,936

SEC source: 0000905148-26-002724 · form4.xml · nonDerivative · entry 1

Ali-Jackson Kamil · CIK 0001654337 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,625

F1 · kind: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025.

SEC source: 0000905148-26-002535 · form4.xml · nonDerivative · entry 1

Wasman Jane · CIK 0001352455 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,250

F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.

SEC source: 0000905148-26-002534 · form4.xml · nonDerivative · entry 1

MOOS WALTER H · CIK 0001190272 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,472

F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.

SEC source: 0000905148-26-002533 · form4.xml · nonDerivative · entry 1

MILLER MICHAEL PATRICK · CIK 0001236514 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,937

F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.

SEC source: 0000905148-26-002532 · form4.xml · nonDerivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,250

F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.

SEC source: 0000905148-26-002531 · form4.xml · nonDerivative · entry 1

HANNAH ALISON L. · CIK 0001645600 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,375

F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.

SEC source: 0000905148-26-002529 · form4.xml · nonDerivative · entry 1

Ali-Jackson Kamil · CIK 0001654337 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,125

F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.

SEC source: 0000905148-26-002530 · form4.xml · nonDerivative · entry 1

Frohlich Mark W · CIK 0001420482 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,000

F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.

SEC source: 0000905148-26-001015 · form4.xml · derivative · entry 3

MOOS WALTER H · CIK 0001190272 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,000 shares

Expires 2026-05-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

F1 · shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

F2 · derivative.exercise_date: The shares vested monthly over twelve (12) months from the grant date of May 11, 2016.

F1 · derivative.underlying_shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

SEC source: 0000905148-26-001015 · form4.xml · nonDerivative · entry 2

MOOS WALTER H · CIK 0001190272 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,722

SEC source: 0000905148-26-001015 · form4.xml · nonDerivative · entry 1

MOOS WALTER H · CIK 0001190272 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,722

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

F1 · price: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

SEC source: 0000905148-26-000956 · form4.xml · nonDerivative · entry 1

Furey Raymond J. · CIK 0001577899 · EVP, GC, CCO & Corp Sec

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,813

F1 · shares: The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026.

SEC source: 0000905148-26-000955 · form4.xml · nonDerivative · entry 1

RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 282,017

F1 · shares: The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026.

SEC source: 0000905148-26-000953 · form4.xml · nonDerivative · entry 1

Rojkjaer Lisa · CIK 0001846460 · EVP, Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,853

F1 · shares: The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026.

SEC source: 0000905148-26-000954 · form4.xml · nonDerivative · entry 1

Santos David A · CIK 0001820066 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,870

F1 · shares: The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026.

SEC source: 0000905148-26-000952 · form4.xml · nonDerivative · entry 1

Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,337

F1 · shares: The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026.

SEC source: 0000905148-26-000676 · form4.xml · nonDerivative · entry 1

Furey Raymond J. · CIK 0001577899 · EVP, GC, CCO & Corp Sec

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,316

SEC source: 0000905148-26-000678 · form4.xml · nonDerivative · entry 1

Schorno Dean L · CIK 0001509688 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,701

SEC source: 0000905148-26-000679 · form4.xml · nonDerivative · entry 1

Santos David A · CIK 0001820066 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,440

SEC source: 0000905148-26-000677 · form4.xml · nonDerivative · entry 1

Rojkjaer Lisa · CIK 0001846460 · EVP, Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,959

SEC source: 0000905148-26-000675 · form4.xml · nonDerivative · entry 1

RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 228,102